Intralenticular Ozurdex® – One Year Later.

Kathleen Schildroth // Publications // Dec 21 2017

PubMed ID: 29515431

Author(s): Regan KA, Blake CR, Lukowski ZL, Iyer SSR. Intralenticular Ozurdex® – one year later. Case Rep Ophthalmol. 2017 Dec 21;8(3):590-594. doi: 10.1159/000485318. eCollection 2017 Sep-Dec. PMID 29515431

Journal: Case Reports In Ophthalmology, Volume 8, Issue 3, 2017

Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity. Macular edema remains resolved 2 months following cataract removal. This is the longest reported period of observation of intralenticular Ozurdex in the literature. Ozurdex remains effective despite intralenticular location, and it can have minimal effects on cataract progression.